Avivomed

Avivomed operates at the intersection of implantable medical devices, sleep medicine, and neuromodulation. Its stated focus is obstructive sleep apnea, particularly patients who cannot tolerate CPAP, the dominant noninvasive treatment approach. That gives the company a clearly defined clinical problem, but also places it in a demanding competitive environment that includes established implantable alternatives such as Inspire’s hypoglossal-nerve stimulation system, alongside CPAP, oral appliances, and surgical interventions. Avivomed’s differentiation is its emphasis on minimally invasive neuromodulation and device concepts that detect the respiration cycle and provide therapeutic feedback. The company’s patent activity indicates an effort to connect stimulation delivery with physiological signals rather than rely solely on fixed treatment parameters. Its positioning is still development-stage: the business is private, has approximately 11–50 employees, and has disclosed one $32 million Series A rather than commercial-scale financing.

Avivomed’s trajectory shows a concentrated progression from formation to technology development and executive transition. Founded in 2021, the company announced a $32 million Series A on Dec 1, 2021, providing substantial early capital for neuromodulation research, device engineering, and clinical development. Its patent record then expanded from therapeutic-feedback concepts published on Jun 16, 2023 to multiple respiration-cycle-detection filings published between Feb 19, 2024 and Nov 11, 2024. These filings suggest an inflection point toward systems designed to adapt stimulation to breathing patterns, a relevant technical direction for sleep-apnea treatment. On Jun 26, 2025, Dan Brounstein took over as CEO and Board Member after Steve Masson’s retirement, marking another transition from founding leadership toward industry-oriented execution. The company remains private and appears to have 11–50 employees, with no disclosed follow-on financing, commercial launch, hiring acceleration, or revenue milestone. Growth therefore appears technology- and clinical-development-led, with future progress likely dependent on validation, regulatory advancement, and adoption evidence that is not publicly available.